BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057 [PMID: 26301047 DOI: 10.4254/wjh.v7.i17.2053]
URL: https://www.wjgnet.com/1948-5182/full/v7/i17/2053.htm
Number Citing Articles
1
David J. Pinato, Matthew W. Brown, Sebastian Trousil, Eric O. Aboagye, Jamie Beaumont, Hua Zhang, Helen M. Coley, Francesco A. Mauri, Rohini Sharma. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinomaBritish Journal of Cancer 2019; 120(5): 512 doi: 10.1038/s41416-018-0373-6
2
Alessandra Mazzola, Andrea Costantino, Salvatore Petta, Tommaso Vincenzo Bartolotta, Maurizio Raineri, Rodolfo Sacco, Giuseppe Brancatelli, Calogero Cammà, Giuseppe Cabibbo. Recurrence of Hepatocellular Carcinoma after Liver Transplantation: An UpdateFuture Oncology 2015; 11(21): 2923 doi: 10.2217/fon.15.239
3
Giuseppe Cabibbo, Maria Reig, Gennaro Gadaleta-Caldarola, Giovanni Galati, Giuseppe Lombardi, GianCarlo Mazza, Luca Marzi, Carlo Saitta, Jean-Charles Nault, Rodolfo Sacco. The Calm Before the Storm: A Report from the International Liver Cancer Association Congress 2015 – Part 2Future Oncology 2016; 12(3): 285 doi: 10.2217/fon.15.324
4
Giuseppe Cabibbo, Salvatore Petta, Marcello Maida, Calogero Cammà. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical PracticeDigestive Diseases 2015; 33(5): 668 doi: 10.1159/000438477
5
David J. Pinato. Breaking Kuhn's paradigm in advanced hepatocellular carcinomaHepatology 2018; 67(5): 1663 doi: 10.1002/hep.29714
6
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaHepatology 2019; 69(5): 2258 doi: 10.1002/hep.30337
7
Rodolfo Sacco, Alessandro Granito, Irene Bargellini, Teresa Zolfino, Carlo Saitta, Luca Marzi, Gherardo Tapete, Giampaolo Bresci, Sara Marinelli, Francesco Tovoli, Simona Attardo, Margherita Rossi, Lucio Urbani, Santino Marchi, Piero Buccianti, Giuseppe Cabibbo. Clinical Outcomes with Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma: A Multicenter Real-Life StudyFuture Oncology 2018; 14(29): 3049 doi: 10.2217/fon-2018-0281
8
D. J. Pinato, C. Yen, D. Bettinger, R. Ramaswami, T. Arizumi, C. Ward, M. Pirisi, M. E. Burlone, R. Thimme, M. Kudo, R. Sharma. The albumin–bilirubin grade improves hepatic reserve estimation post‐sorafenib failure: implications for drug developmentAlimentary Pharmacology & Therapeutics 2017; 45(5): 714 doi: 10.1111/apt.13904
9
David J. Pinato. Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinomaOncogene 2018; 37(34): 4635 doi: 10.1038/s41388-018-0262-8
10
Catia Giovannini, Manuela Minguzzi, Filippo Genovese, Michele Baglioni, Alessandra Gualandi, Matteo Ravaioli, Maddalena Milazzo, Simona Tavolari, Luigi Bolondi, Laura Gramantieri. Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinomaOncotarget 2016; 7(26): 39609 doi: 10.18632/oncotarget.9203